CIM
TEVA icon

Contravisory Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Contravisory Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,992
Closed -$154K – 446
2025
Q1 		$154K Sell
9,992
-17
-0.2% -$304 0.03% 257
2024
Q4 		$221K Buy
+10,009
New +$182K 0.05% 214
2016
Q2 		– Sell
-127
Closed -$7K – 231
2016
Q1 		$7K Hold
127
– – ﹤0.01% 131
2015
Q4 		$8K Buy
127
+45
+55% +$2.78K ﹤0.01% 130
2015
Q3 		$5K Sell
82
-210
-72% -$13.6K ﹤0.01% 151
2015
Q2 		$17K Buy
+292
New +$18K ﹤0.01% 133

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Contravisory Investment Management's TEVA Position: Q2 2025 in Review

Contravisory Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 9,992 shares — an estimated $154K sold.

Contravisory Investment Management first reported a position in TEVA in Q2 2015 and held it in 6 quarters. The position peaked at $221K in Q4 2024. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Contravisory Investment Management reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Contravisory Investment Management sold 9,992 Teva Pharmaceuticals shares in Q2 2025, an estimated $154K.
  • Contravisory Investment Management first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 6 quarters.
  • Contravisory Investment Management's Teva Pharmaceuticals position peaked at $221K in Q4 2024.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Contravisory Investment Management's 13F filing for Q2 2025, filed 10 Jul 2025.